Medicxi Ventures Management (Jersey) LTD Phathom Pharmaceuticals, Inc. Transaction History
Medicxi Ventures Management (Jersey) LTD
- $381 Million
- Q1 2024
A detailed history of Medicxi Ventures Management (Jersey) LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Medicxi Ventures Management (Jersey) LTD holds 7,464,572 shares of PHAT stock, worth $76.5 Million. This represents 20.79% of its overall portfolio holdings.
Number of Shares
7,464,572
Previous 3,760,869
98.48%
Holding current value
$76.5 Million
Previous $34.3 Million
130.87%
% of portfolio
20.79%
Previous 13.0%
Shares
5 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$35.8 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.1 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT2.28MShares$23.4 Million0.04% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $402M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...